{"id":390056,"date":"2021-04-01T00:00:00","date_gmt":"2021-04-01T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0005-2020-biopharma-psoriasis-disease-landscape-and-forecast-g7-2020\/"},"modified":"2026-04-22T05:22:18","modified_gmt":"2026-04-22T05:22:18","slug":"dlsfim0005-2020-biopharma-psoriasis-disease-landscape-and-forecast-g7-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0005-2020-biopharma-psoriasis-disease-landscape-and-forecast-g7-2020\/","title":{"rendered":"Psoriasis | Disease Landscape and Forecast | G7 | 2020"},"content":{"rendered":"<p>The psoriasis therapy market is becoming increasingly lucrative owing to the growing number of approved biologics. Although TNF-alpha inhibitors continue to dominate the market, their premier position is being challenged by the IL-17 inhibitors secukinumab (Novartis\u2019s Cosentyx), ixekizumab (Eli Lilly\u2019s Taltz), and brodalumab (Bausch Health\u2019s Siliq, Leo Pharma\u2019s Kyntheum, Kyowa Hakko Kirin\u2019s Lumicef) and by the IL-12\/23 inhibitor ustekinumab (Janssen\u2019s Stelara). With the approvals of the IL-23 inhibitors guselkumab (Janssen\u2019s Tremfya), tildrakizumab (Merck &#038; Co. \/ Almirall \/ Sun Pharma\u2019s Ilumya \/ Ilumetri), and, more recently, risankizumab (AbbVie \/ Boehringer\u00a0Ingelheim\u2019s\u00a0Skyrizi), another effective drug class has been introduced to this competitive market. The landscape for the established biologics will change even further with the increasing availability and use of biosimilars.<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<ul>\n<li>How do interviewed KOLs view the efficacy and safety of the IL-17 inhibitors Cosentyx, Taltz, and Siliq \/ Kyntheum \/ Lumicef and the emerging IL-17 A\/F dual inhibitor, UCB\u2019s bimekizumab, and where are \/ will these agents be positioned in the psoriasis treatment algorithm?<\/li>\n<li>What will be the impact of the IL-23 inhibitors Tremfya, Ilumya, Skyrizi, and Eli Lilly&#8217;s emerging therapy\u00a0mirikizumab, and how will they fare in the competitive psoriasis market?<\/li>\n<li>How is the oral agent apremilast (Amgen\u2019s Otezla) used to treat\u00a0psoriasis, and how will it\u00a0 compare\u00a0to\u00a0BMS&#8217;s emerging oral TYK2 inhibitor,\u00a0BMS-986165?<\/li>\n<li>How fast will uptake of biosimilars occur in psoriasis, and which brands will see\u00a0the most erosion in patient share and sales?<\/li>\n<\/ul>\n<p><strong>Geographies:<\/strong> United States, France, Germany, Italy, Spain, United Kingdom, and Japan.<\/p>\n<p><strong>Primary research:<\/strong>\u00a024\u00a0country-specific interviews with thought leaders. Supported by survey data collected for this and other DRG research.<\/p>\n<p><strong>Epidemiology:<\/strong> Total diagnosed prevalence of psoriasis by country, segmented by mild and moderate to severe subpopulations.<\/p>\n<p><strong>Emerging therapies:<\/strong> Phase III\/PR: 7\u00a0drugs; Phase II: 9\u00a0drugs; coverage of select preclinical and Phase I products.<\/p>\n<p><strong>Forecast: <\/strong> 10-year, annualized, drug-level sales and patient share of key psoriasis therapies through 2029, segmented by brands\/generics and epidemiological subpopulations.<\/p>\n<p><strong>Product Description:<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390056","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriasis","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390056\/revisions"}],"predecessor-version":[{"id":576424,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390056\/revisions\/576424"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}